Accounts Receivable, after Allowance for Credit Loss, Current in USD of Sonnet BioTherapeutics Holdings, Inc. from Q4 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Sonnet BioTherapeutics Holdings, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and change rate from Q4 2010 to Q1 2025.
  • Sonnet BioTherapeutics Holdings, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Mar 2025 was $500,000.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Sonnet BioTherapeutics Holdings, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $500,000 31 Mar 2025 10-Q 13 May 2025 2025 Q2
Q3 2019 $223,959 -$141,071 -39% 30 Sep 2019 10-Q 14 Nov 2019 2019 Q3
Q2 2019 $518,930 -$122,672 -19% 30 Jun 2019 10-Q 14 Aug 2019 2019 Q2
Q1 2019 $523,437 +$178,668 +52% 31 Mar 2019 10-Q 15 May 2019 2019 Q1
Q4 2018 $387,239 -$88,749 -19% 31 Dec 2018 10-Q 14 Nov 2019 2019 Q3
Q3 2018 $365,030 +$89,825 +33% 30 Sep 2018 10-Q 14 Nov 2018 2018 Q3
Q2 2018 $641,602 +$311,547 +94% 30 Jun 2018 10-Q 13 Aug 2018 2018 Q2
Q1 2018 $344,769 -$4,234 -1.2% 31 Mar 2018 10-Q 15 May 2018 2018 Q1
Q4 2017 $475,988 -$48,493 -9.2% 31 Dec 2017 10-K 01 Apr 2019 2018 FY
Q3 2017 $275,205 +$52,450 +24% 30 Sep 2017 10-Q 13 Nov 2017 2017 Q3
Q2 2017 $330,055 -$500,485 -60% 30 Jun 2017 10-Q 14 Aug 2017 2017 Q2
Q1 2017 $349,003 -$607,738 -64% 31 Mar 2017 10-Q 15 May 2017 2017 Q1
Q4 2016 $524,481 -$338,454 -39% 31 Dec 2016 10-K 30 Mar 2018 2017 FY
Q3 2016 $222,755 +$28,166 +14% 30 Sep 2016 10-Q 10 Nov 2016 2016 Q3
Q2 2016 $830,540 +$417,067 +101% 30 Jun 2016 10-Q 11 Aug 2016 2016 Q2
Q1 2016 $956,741 +$647,679 +210% 31 Mar 2016 10-Q 16 May 2016 2016 Q1
Q4 2015 $862,935 +$549,426 +175% 31 Dec 2015 10-K 31 Mar 2017 2016 FY
Q3 2015 $194,589 -$191,556 -50% 30 Sep 2015 10-Q 16 Nov 2015 2015 Q3
Q2 2015 $413,473 +$295,119 +249% 30 Jun 2015 10-Q 14 Aug 2015 2015 Q2
Q1 2015 $309,062 +$135,199 +78% 31 Mar 2015 10-Q 20 May 2015 2015 Q1
Q4 2014 $313,509 +$86,328 +38% 31 Dec 2014 10-K 31 Mar 2016 2015 FY
Q3 2014 $386,145 +$229,910 +147% 30 Sep 2014 10-Q 14 Nov 2014 2014 Q3
Q2 2014 $118,354 -$16,383 -12% 30 Jun 2014 10-Q 14 Aug 2014 2014 Q2
Q1 2014 $173,863 +$101,735 +141% 31 Mar 2014 10-Q 15 May 2014 2014 Q1
Q4 2013 $227,181 +$66,108 +41% 31 Dec 2013 10-K 15 Apr 2015 2014 FY
Q3 2013 $156,235 +$36,653 +31% 30 Sep 2013 10-Q 15 Nov 2013 2013 Q3
Q2 2013 $134,737 +$56,641 +73% 30 Jun 2013 10-Q 12 Aug 2013 2013 Q2
Q1 2013 $72,128 +$16,997 +31% 31 Mar 2013 10-Q 15 May 2013 2013 Q1
Q4 2012 $161,073 +$52,359 +48% 31 Dec 2012 10-K 31 Mar 2014 2013 FY
Q3 2012 $119,582 +$52,915 +79% 30 Sep 2012 10-Q/A 31 Dec 2012 2012 Q3
Q2 2012 $78,096 +$36,429 +87% 30 Jun 2012 10-Q/A 02 Jan 2013 2012 Q2
Q1 2012 $55,131 31 Mar 2012 10-Q/A 28 Dec 2012 2012 Q1
Q4 2011 $108,714 +$104,456 +2453% 31 Dec 2011 10-K 03 Apr 2013 2012 FY
Q3 2011 $66,667 30 Sep 2011 10-Q 14 Nov 2011 2011 Q3
Q2 2011 $41,667 30 Jun 2011 10-Q 15 Aug 2011 2011 Q2
Q4 2010 $4,258 31 Dec 2010 10-K/A 28 Dec 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.